Search
Levoketoconazole
go.drugbank.com/drugs/DB05667ApprovedIt possesses most of the inhibitory effect towards steroidogenic enzymes, making it an attractive candidate for CS treatment with a potentially lower toxicity profile than its racemate. … Still, toxicity has limited its use, notably hepatic toxicity and a tendency to prolong the QT interval.[A244083] Levoketoconazole is one of two enantiomers present in racemic [ketoconazole].
Categories: Corticosteroids for Systemic UseSarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigational[A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid … arthritis (RA) in combination with methotrexate.
Categories: Biologics for Rheumatoid Arthritis TreatmentProducts: KEVZARA Solution for Injection in Pre-filled Pen 150mg, KEVZARA Solution for Injection in Pre-filled Pen 200mgRurioctocog alfa pegol
go.drugbank.com/drugs/DB16007ApprovedInvestigationalFactor VIII is an essential protein involved in normal blood clotting; thus, a deficient level of functional factor VIII is associated with an elevated risk for excessive bleeding caused by spontaneous … or secondary events like trauma or surgery.
Products: ADYNOVATE 1500IU Powder and Solvent for Solution for Injection, ADYNOVATE 2000IU Powder and Solvent for Solution for InjectionFlibanserin
go.drugbank.com/drugs/DB04908ApprovedInvestigationalIn February of 2018 Flibanserin was approved by Health Canada under the brand name Addyi for a similar indication as approved by the FDA. … In December of 2025 the FDA expanded the age of the indication to include postmenopausal women, a first for the FDA and sexual health in that age group. [L54893]
N-alkyl ethylbenzyl dimethyl ammonium (C12-C14)
go.drugbank.com/drugs/DB11202ApprovedIt is found in sanitizing solutions or soaps as an active ingredient due to its antimicrobial properties. … Employed in a great variety of cleaning agents and sanitizing agents, it possesses relatively broad gram-positive and gram-negative antibacterial activities and relatively little chance for systemic absorption
Salts: N-alkyl ethylbenzyl dimethyl ammonium chloride (C12-C14)Mixtures: E-2 Cleanser Sanitizer, All Star Antiseptic Hand Soap E-2Pretomanid
go.drugbank.com/drugs/DB05154ApprovedInvestigationalPersistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. … [L8048,L8066] Unlike other therapeutic regimens for the treatment of resistant TB, which may take 18 months or longer and may not be effective, the pretomanid-containing regimen allows for a more efficacious
Categories: Antiinfectives for Systemic Use, Drugs for Treatment of TuberculosisCatumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnCatumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. … Catumaxumab was approved for market in Canada in May 2012 for the same condition [FDA Label]. It is currently available under the brand name Removab.
Tegaserod
go.drugbank.com/drugs/DB01079ApprovedWithdrawnin female patients less than 65 years of age and whom are considered to be at a lower risk of a cardiovascular event than the broader population. … [L5918,F4229] Since then, closer evaluations of the original data suggesting such cardiovascular risk have resulted in the limited reintroduction or 're-approval' of tegaserod for treatment of IBS-C specifically
Categories: Drugs for ConstipationBebtelovimab
go.drugbank.com/drugs/DB16755ApprovedWithdrawnBebtelovimab (LY-COV1404, LY-3853113) is a human monoclonal antibody approved for emergency use in the treatment of COVID-19. … [L43827] On November 30, 2022, the EUA for bebtelovimab was officially withdrawn due to a lack of efficacy against Omicron subvariants, therefore bebtelovimab is no longer authorized for emergency use
Categories: Approved Treatments for COVID-19Temozolomide
go.drugbank.com/drugs/DB00853ApprovedInvestigationalRefractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. … [A229853, A229888, A229923, L32033] Following initial hydrolysis, further reactions liberate a highly reactive methyl diazonium cation capable of methylating various residues on adenosine and guanine bases
Categories: P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: TEMODAL 140MG HKP IN BTL, TEMODAL 180MG HKP IN BTL